The goal of molecular testing for indeterminate thyroid nodules (ITNs) is to accurately distinguish patients who would likely benefit from conservative management from those who would benefit from surgical intervention. When incorporated into molecular assessment of ITNs, quantitative microRNA expression has been shown to improve the prediction of nodule status over reliance on mutation detection alone.
We analyzed the value of microRNA pairwise expression analysis, using two new microRNA Profilers (Benign/Malignant and Specific Strong-driver) in conjunction with MPTX (Multiplatform testing with ThyGeNEXT® + ThyraMIR®)